About the Study

Juvenile Spondyloarthritis: A study to Compare the Likelihood of Disease Flare Associated with Continuing, Tapering, or Stopping Medication in Children

• 8-21 years of age • patients must have been diagnosed with Juvenile Spondyloarthritis • patients must be currently taking a TNFi medication (Adalimumab, Certolizumab, Etanercept, Golumumab, Infliximab) • patients must not have active disease for a minimum of 6 months Patients who participate will be randomly assigned to either continue their current medication schedule, taper down their current medication schedule, or completely stop their medication. The patient will follow their routine care schedule approximately every 3 months, and monitored for any flare of disease.

Interested in learning more?

Full Study Name: Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis